Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis

Shemer, Avner; Gupta, Aditya K.; Kamshov, Shoni; Babaev, Meir; Hermush, Vered; Farhi, Renata; Daniel, C. Ralph; Foley, Kelly A.

doi:10.1080/09546634.2019.1654598

Cited by 6 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our search yielded 8 articles which fit our inclusion criteria and were assessed for the treatment of various NDMs causing onychomycosis. 86,94,98,[126][127][128][129][130] The treatment methods along with their cure rates for NDM toenail onychomycosis from clinical studies are summarized in Table 3. 86,[126][127][128][129] Scopulariopsis brevicaulis causing toenail onychomycosis has been treated with several antifungal agents with varying results.…”

Section: Treatmentmentioning

confidence: 99%

“…We identified 201 articles which were screened for data pertaining to treatment of NDM onychomycosis. Our search yielded 8 articles which fit our inclusion criteria and were assessed for the treatment of various NDMs causing onychomycosis 86,94,98,126–130 . The treatment methods along with their cure rates for NDM toenail onychomycosis from clinical studies are summarized in Table 3 86,126–129 …”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Nondermatophyte mould onychomycosis

Gupta

Summerbell

Venkataraman

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Nondermatophyte moulds (NDMs) onychomycosis is often difficult to diagnose as NDMs have been considered contaminants of nails. There are several diagnostic methods used to identify NDMs, however, repeated laboratory isolation is recommended to validate pathogenicity. With NDM and mixed infection (dermatophytes plus NDM) onychomycosis on the rise, accurate clinical diagnosis along with mycological tests is recommended. Systemic antifungal agents such as itraconazole and terbinafine (e.g. pulse regimen: 1 pulse = every day for one week, followed by no treatment for three weeks) have shown efficacy in treating onychomycosis caused by various NDMs such as Aspergillus spp., Fusarium spp., Scopulariopsis brevicaulis, and Onychocola canadensis. Studies investigating topical therapy and devices for NDM onychomycosis are limited. The emergence of antifungal resistance necessitates the incorporation of antifungal susceptibility testing into diagnosis when possible, for the management of recalcitrant infections. Case studies documented in the literature show newer azoles such as posaconazole and voriconazole as sometimes effective in treating resistant NDM onychomycosis. Treatment with broad-spectrum antifungal agents (e.g. itraconazole and efinaconazole) and other combination therapy (oral + oral and/or oral + topical) may be considerations in the management of NDM onychomycosis.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Nondermatophyte mould onychomycosis

Gupta

Summerbell

Venkataraman

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Side-effects were recorded during each session of PDT. As reported by Shemer et al, 14 treatment success and clinical improvement can also be tabulated to achieve a more complete analysis of the results. In this way, treatment success was defined as mycological cure + less than 10% of nail affected.…”

Section: Mal/pdt Protocolmentioning

confidence: 99%

Methylene blue vs methyl aminolevulinate photodynamic therapy in the treatment of mild‐to‐moderate toenail onychomycosis: Short‐ and medium‐term effects

Alberdi¹,

Gómez

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has emerged as an interesting alternative option for onychomycosis treatment. The impact of a specific photosensitizer (PS) on the final result is an important factor to consider. We conducted a short-and medium-term controlled trial to compare the effectiveness of PDT in the treatment of mild-tomoderate onychomycosis when it is mediated by two different PSs. Twenty patients were randomized to receive nine sessions of PDT distributed over 16 weeks mediated either by methylene blue (MB/PDT group) or methyl aminolevulinate (MAL/ PDT group). Onychomycosis severity index (OSI) and nail involvement were checked along the study. Complete cure, treatment success, and clinical improvement were tabulated at 16 and 40-week follow-ups. OSI scores decreased significantly along the study, from 12.1 ± 5.4 to 3.6 ± 3.2 (MB/PDT group) and from 14.8 ± 6.0 to 5.4 ± 4.4 (MAL/PDT group). At 16-week follow-up, only 20% of the patients in the MB/PDT group reached complete cure and none in the group of MAL/PDT. At 40-week follow-up, complete cure rates were 70% and 40% in the MB/PDT group and MAL/PDT group respectively. Both modalities showed good outcomes in treatment of moderate toenail onychomycosis. MB/PDT showed a faster action but with relapse rates slightly higher than MAL/PDT.

show abstract

“…With regards to non‐dermatophyte onychomycosis infections, there have been few investigations on their treatment outcomes and prognostic predictors. Fusarium spp., Aspergillus spp., Scopulariopsis brevicaulis and mixed non‐dermatophyte infections were the most commonly found causative moulds in treatment and treatment‐outcome studies 2,14 . It has also been reported that poor prognoses of mycological cure in non‐dermatophyte onychomycosis were associated with male sex, baseline severity, and presence of atherosclerosis or hyperlipidaemia 14 .…”

Section: Introductionmentioning

confidence: 99%

“…Mycological cure rates for non‐dermatophyte nail infections treated with systemic antifungal agents have ranged from approximately 30% to 70% 6 . Additionally, the time to mycological cure for non‐dermatophyte nail infections was significantly longer than for dermatophyte infections 2,14 …”

Section: Introductionmentioning

confidence: 99%

Prognostic factors for mycological cure in patients with onychomycosis caused by Neoscytalidium dimidiatum: A retrospective cohort study

Leeyaphan

Chai‐Adisaksopha

Tovanabutra

et al. 2023

Mycoses

View full text Add to dashboard Cite

The prevalence of onychomycosis caused by non-dermatophyte infections is increasing. [1][2][3][4][5][6] Neoscytalidium dimidiatum is a major causative organism of non-dermatophyte skin and nail infections worldwide, especially in South America, Africa, Europe and Asia. 4,5,[7][8][9][10][11] Neoscytalidium dimidiatum infection rates were reported as 34% in France, 22% in Tobago and 9%-12% in Nigeria. 12 In Thailand, 20% of fungal foot infections and 36% of nail infections were due to N. dimidiatum. 2 The organism is generally regarded as

show abstract

Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis

Cited by 6 publications

References 27 publications

Nondermatophyte mould onychomycosis

Nondermatophyte mould onychomycosis

Methylene blue vs methyl aminolevulinate photodynamic therapy in the treatment of mild‐to‐moderate toenail onychomycosis: Short‐ and medium‐term effects

Prognostic factors for mycological cure in patients with onychomycosis caused by Neoscytalidium dimidiatum: A retrospective cohort study

Contact Info

Product

Resources

About